Skip to content

ORAL VERSUS IV IRON THERAPY IN PATIENTS WITH KIDNEY DISEASE

COMPARISON OF ORAL VERSUS INTRAVENOUS IRON THERAPY IN IMPROVING HEMOGLOBIN STATUS IN PATIENTS OF CHRONIC KIDNEY DISEASE

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231003059605N1
Enrollment
210
Registered
2023-10-31
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease. Anemia in chronic kidney disease

Interventions

Intervention 1: Intervention group: Intravenous iron supplementation group. Intervention 2: Intervention group: Oral iron intervention group.

Sponsors

Pak Emirates Military Hospital Rawalpindi
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria included all male and female patients over the age of 18 years Not on hemodialysis or erythropoietin diagnosed as anemia with a baseline Hb of less than 13 g/dl in males and less than 12 g/dl in females With established chronic kidney disease with a GFR (glomerular filtration rate) of less than 60ml/min for more than 90 days assessed using the CKD-EPI equation and/or hyper albuminuria with urine albumin ? 30 mg in 24 hours or urine albumin to creatinine ratio (ACR) ? 30 mg/g.

Exclusion criteria

Exclusion criteria: Exclusion criteria included patients on dialysis, erythropoietin or use of erythropoietin stimulating agents (ESAs) in the last 3 months Patients with advanced liver, cardiac or ESKD (end-stage kidney disease) Drug allergies to iron and its supplemental form during therapy or previous known history Unwilling to be included in the study.

Design outcomes

Primary

MeasureTime frame
Serum iron levels. Timepoint: 4 weeks after starting therapy. Method of measurement: Blood levels.;Serum Hb. Timepoint: 4 weeks after therapy. Method of measurement: Blood levels.;Serum Ferritin levels. Timepoint: 4 weeks after therapy. Method of measurement: Blood levels.;Serum transferrin and TIBC levels. Timepoint: 4 weeks after therapy. Method of measurement: Blood levels.

Secondary

MeasureTime frame
Constipation and diarrhea. Timepoint: During 4 weeks of therapy. Method of measurement: Patient history.;Allergy to iron supplementation. Timepoint: During 4 weeks of therapy. Method of measurement: Patient assessment weekly during treatment.

Countries

Pakistan

Contacts

Public ContactHamza Nawaz Chattha

Pak Emirates Military Hospital Rawalpindi

Hamzanawazchattha@gmail.com+92 324 5972040

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026